{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:17:19Z","timestamp":1794579439643,"version":"4.9.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.semarthrit.2022.151955","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T04:45:26Z","timestamp":1641789926000},"page":"151955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Long-term abatacept treatment for 48 weeks in patients with primary Sj\u00f6gren's syndrome: The open-label extension phase of the ASAP-III trial"],"prefix":"10.1016","volume":"53","author":[{"given":"Liseth","family":"de Wolff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien F.","family":"van Nimwegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Mossel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greetje S.","family":"van Zuiden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alja J.","family":"Stel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalle I.","family":"Majoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette","family":"Olie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonoor I.","family":"Los","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan","family":"Vissink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred K.L.","family":"Spijkervet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenny M.P.J.","family":"Verstappen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans G.M.","family":"Kroese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Arends","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrika","family":"Bootsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.semarthrit.2022.151955_bib0001","first-page":"97","article-title":"Systemic manifestations of primary Sj\u00f6gren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients","volume":"37","author":"Retamozo","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.151955_bib0002","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sj\u00f6gren's syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151955_bib0003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sj\u00f6gren's syndrome with topical and systemic therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.151955_bib0004","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2013-204653","article-title":"Abatacept treatment reduces disease activity in early primary Sj\u00f6gren's syndrome (open-label proof of concept ASAP study)","volume":"73","author":"Meiners","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.151955_bib0005","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1002\/acr.22052","article-title":"Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sj\u00f6gren's syndrome: a pilot study","volume":"65","author":"Adler","year":"2013","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151955_bib0006","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10067-019-04724-w","article-title":"Effectiveness and safety of abatacept for the treatment of patients with primary Sj\u00f6gren's syndrome","volume":"39","author":"Machado","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"19","key":"10.1016\/j.semarthrit.2022.151955_bib0007","first-page":"1","article-title":"Abatacept treatment for patients with early active primary Sj\u00f6gren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)","volume":"9913","author":"van Nimwegen","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151955_bib0008","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2020-218599","article-title":"Efficacy and safety of abatacept in active primary Sj\u00f6gren's syndrome: results of a phase III, randomised, placebo-controlled trial","volume":"80","author":"Baer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.151955_bib0009","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S2665-9913(21)00122-3","article-title":"Composite of relevant endpoints for Sj\u00f6gren\u2019s syndrome (CRESS): development and validation of a novel outcome measure","volume":"3","author":"Arends","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.151955_bib0010","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sj\u00f6gren's syndrome: a revised version of the European criteria proposed by the American-European consensus group","volume":"61","author":"Daniels","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151955_bib0011","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren's syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"76","author":"Shiboski","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.151955_bib0012","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/ard.2009.110619","article-title":"EULAR Sj\u00f6gren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sj\u00f6gren's syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.151955_bib0013","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sj\u00f6gren's syndrome patient reported index (ESSPRI): development of a consensus patient index for primary Sj\u00f6gren's syndrome","volume":"70","author":"Seror","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.151955_bib0014","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ajo.2009.09.013","article-title":"A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sj\u00f6gren\u2019s syndrome international registry","volume":"149","author":"Whitcher","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151955_bib0015","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","article-title":"TFOS DEWS II diagnostic methodology report","volume":"15","author":"Wolffsohn","year":"2017","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151955_bib0016","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ejrad.2007.02.003","article-title":"Ultrasonographic changes of major salivary glands in primary Sj\u00f6gren's syndrome. Evaluation of a novel scoring system","volume":"63","author":"Ho\u010devar","year":"2007","journal-title":"Eur J Radiol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151955_bib0017","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/annrheumdis-2014-206008","article-title":"Defining disease activity states and clinically meaningful improvement in primary Sj\u00f6gren's syndrome with EULAR primary Sj\u00f6gren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)","volume":"75","author":"Seror","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151955_bib0018","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3899\/jrheum.200482","article-title":"Clinical phenotyping of primary Sj\u00f6gren\u2019s patients using salivary gland ultrasonography \u2013 data from the RESULT cohort","volume":"48","author":"Mossel","year":"2021","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151955_bib0019","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/acr.22720","article-title":"Fatigue in primary Sj\u00f6gren's syndrome: clinical, laboratory, psychometric, and biologic associations","volume":"68","author":"Karageorgas","year":"2016","journal-title":"Arthritis Care Res"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.151955_bib0020","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1093\/rheumatology\/keu522","article-title":"The impact of primary Sj\u00f6gren's syndrome on female sexual function","volume":"54","author":"Van Nimwegen","year":"2015","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151955_bib0021","first-page":"317","article-title":"Abatacept treatment of patients with primary Sj\u00f6gren's syndrome results in a decrease of germinal centres in salivary gland tissue","volume":"35","author":"Haacke","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.151955_bib0022","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2020-218467","article-title":"Interleukin 6 receptor inhibition in primary Sj\u00f6gren syndrome: a multicentre double-blind randomised placebo-controlled trial","volume":"80","author":"Felten","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.151955_bib0023","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sj\u00f6gren's syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151955_bib0024","first-page":"6","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab a randomized trial","volume":"29","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"issue":"21","key":"10.1016\/j.semarthrit.2022.151955_bib0025","first-page":"1","article-title":"CRESS: improving the assessment of disease activity in Sj\u00f6gren's syndrome","volume":"9913","author":"Isenberg","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151955_bib0026","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/S2665-9913(19)30042-6","article-title":"Symptom-based stratification of patients with primary Sj\u00f6gren's syndrome: multi-dimensional characterisation of international observational cohorts and re analyses of randomised clinical trials","volume":"1","author":"Tarn","year":"2019","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151955_bib0027","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23472-7","article-title":"A new molecular classification to drive precision treatment strategies in primary Sj\u00f6gren\u2019s syndrome","volume":"12","author":"Soret","year":"2021","journal-title":"Nat Commun"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222000063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222000063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:07:42Z","timestamp":1758733662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017222000063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":27,"alternative-id":["S0049017222000063"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151955","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term abatacept treatment for 48 weeks in patients with primary Sj\u00f6gren's syndrome: The open-label extension phase of the ASAP-III trial","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151955","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151955"}}